Fig. 3: The synergistic effect of venetoclax combined with anti-ROR1 mAbs in CLL.
From: Therapeutic advances in the targeting of ROR1 in hematological cancers
Both therapies lead to an increased apoptosis with a synergistic effect when used as a combine therapy.
